Peroxisome proliferator‐activated receptor γ coactivator‐1α in heart disease (Review)

Siyu Sun,Huige Guo,Guohui Chen,Hui Zhang,Zhanrui Zhang,Xiulong Wang,Dongxu Li,Xuefang Li,Guoan Zhao,Fei Lin
DOI: https://doi.org/10.3892/mmr.2024.13382
IF: 3.423
2024-11-05
Molecular Medicine Reports
Abstract:Heart disease (HD) is a general term for various diseases affecting the heart. An increasing body of evidence suggests that the pathogenesis of HD is closely related to mitochondrial dysfunction. Peroxisome proliferator‐activated receptor γ coactivator‐1α (PGC‐1α) is a transcriptional coactivator that plays an important role in mitochondrial function by regulating mitochondrial biogenesis, energy metabolism and oxidative stress. The present review shows that PGC‐1α expression and activity in the heart are controlled by multiple signaling pathways, including adenosine monophosphate‐activated protein kinase, sirtuin 1/3 and nuclear factor κB. These can mediate the activation or inhibition of transcription and post‐translational modifications (such as phosphorylation and acetylation) of PGC‐1α. Furthermore, it highlighted the recent progress of PGC‐1α in HD, including heart failure, coronary heart disease, diabetic cardiomyopathy, drug‐induced cardiotoxicity and arrhythmia. Understanding the mechanisms underlying PGC‐1α in response to pathological stimulation may prove to be beneficial in developing new ideas and strategies for preventing and treating HDs. Meanwhile, the present review explored why the opposite results occurred when PGC‐1α was used as a target therapy.
oncology,medicine, research & experimental
What problem does this paper attempt to address?